SEC Form 4 · accession 0001140361-18-033744
Aquestive Therapeutics, Inc. · AQST
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Keith J Kendall
Officer — CEO and President · Director
Period of report
Jul 24, 2018
Accepted (ET)
Jul 26, 2018 · 9:13 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001398733
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Purchase)F1 | $15.00 | Jul 24, 2018 | A | 240,165 | A | — | Jul 24, 2028 | Common Stock | 240,165 | 240,165 | D |
| Restricted Stock UnitF2,F3 | — | Jul 24, 2018 | A | 116,576 | A | — | — | Common Stock | 116,576 | 116,576 | D |
Explanation of responses
- F1The shares underlying the options vest in 36 equal (or as nearly equal as possible) monthly installments beginning on August 31, 2018, subject in each case to Mr. Kendall's continuous service with the Issuer from the grant date through the applicable vesting date.
- F2Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- F3The restricted stock units vest in 8 equal (or as nearly equal as possible) quarterly installments beginning on August 31, 2018, subject in each case to Mr. Kendall's continuous service with the Issuer from the grant date through the applicable vesting date. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date thereof.